glp-1 heart muscle medications are known for their weight-loss effects, but fewer people may know that they could benefit the too. In fact, Wegovy was approved by the FDA to reduce the risk The Cardiovascular Biology of Glucagon-like

With the advent of recombinant peptide synthesis in the 1970s, scientists not only began working on isolating the gene responsible for insulin production but fabricating it outside the body

2030 (USD BILLION) FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS

Important note: This table provides a general overview and shouldn't be relied upon for legal compliance

Lose 15% of your body weight with GLP-1s * Lose 15% of your body weight with GLP-1s * *In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, the treatment group receiving semaglutide experienced a mean body weight loss of 15%, compared to 2% of the placebo group

Hers also provides compounded tirzepatide at $299-$399 per month, matching or beating Willow at most dose levels

Those include Ozempic and its sister drug approved for obesity, Wegovy, which use semaglutide, and Mounjaro and Zepbound, for diabetes and obesity, respectively, which use the active ingredient tirzepatide